close
close

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025 Seite 1

Posted on by Vaseline
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025 Seite 1

Definitive agreement with Aditxt, if approved by Appili shareholders, provides significant premium to shareholders and resources to advance key programs

ATI-1701 funding commitments from U.S. Air Force Academy and interactions with the U.S. Food and Drug Administration, confirming the development pathway through IND submission

Related Posts